Published in PLoS One on February 15, 2010
Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci U S A (2011) 1.09
Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb Perspect Med (2013) 1.01
Contribution of individual Ebp Pilus subunits of Enterococcus faecalis OG1RF to pilus biogenesis, biofilm formation and urinary tract infection. PLoS One (2013) 0.95
CsrRS and environmental pH regulate group B streptococcus adherence to human epithelial cells and extracellular matrix. Infect Immun (2012) 0.89
Biofilm formation by Streptococcus agalactiae: influence of environmental conditions and implicated virulence factors. Front Cell Infect Microbiol (2015) 0.89
Structural basis for group B streptococcus pilus 1 sortases C regulation and specificity. PLoS One (2012) 0.86
Commensal Streptococcus agalactiae isolated from patients seen at University Hospital of Londrina, Paraná, Brazil: capsular types, genotyping, antimicrobial susceptibility and virulence determinants. BMC Microbiol (2013) 0.86
The GBS PI-2a pilus is required for virulence in mice neonates. PLoS One (2011) 0.85
Pilus distribution among lineages of group b streptococcus: an evolutionary and clinical perspective. BMC Microbiol (2014) 0.85
Regulation and function of pilus island 1 in group B streptococcus. J Bacteriol (2012) 0.84
Acidic pH strongly enhances in vitro biofilm formation by a subset of hypervirulent ST-17 Streptococcus agalactiae strains. Appl Environ Microbiol (2014) 0.84
Sortase A substrate specificity in GBS pilus 2a cell wall anchoring. PLoS One (2011) 0.83
BsaB, a novel adherence factor of group B Streptococcus. Infect Immun (2013) 0.83
The enhancement of biofilm formation in Group B streptococcal isolates at vaginal pH. Med Microbiol Immunol (2012) 0.82
Characterization of host immunity during persistent vaginal colonization by Group B Streptococcus. Mucosal Immunol (2015) 0.81
Structure and assembly of group B streptococcus pilus 2b backbone protein. PLoS One (2015) 0.80
Association between genotypic diversity and biofilm production in group B Streptococcus. BMC Microbiol (2016) 0.79
Distribution of pilus islands and alpha-like protein genes of group B Streptococcus colonized in pregnant women in Beijing, China. Eur J Clin Microbiol Infect Dis (2015) 0.78
Pilus biogenesis of Gram-positive bacteria: Roles of sortases and implications for assembly. Protein Sci (2017) 0.76
Molecular Characterization of Streptococcus agalactiae Causing Community- and Hospital-Acquired Infections in Shanghai, China. Front Microbiol (2016) 0.75
Regulation of PI-2b Pilus Expression in Hypervirulent Streptococcus agalactiae ST-17 BM110. PLoS One (2017) 0.75
Molecular epidemiology of Streptococcus agalactiae isolated from mastitis in Brazilian dairy herds. Braz J Microbiol (2017) 0.75
Acid Stress Response Mechanisms of Group B Streptococci. Front Cell Infect Microbiol (2017) 0.75
Bacterial biofilms: a common cause of persistent infections. Science (1999) 40.82
Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol (2004) 18.85
Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev (2002) 17.58
Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. Mol Microbiol (1998) 17.38
Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. Biotechniques (1990) 13.62
Biofilm formation as microbial development. Annu Rev Microbiol (2000) 13.33
Biofilms as complex differentiated communities. Annu Rev Microbiol (2002) 9.31
Persister cells, dormancy and infectious disease. Nat Rev Microbiol (2006) 8.35
Biofilms: the matrix revisited. Trends Microbiol (2005) 6.66
Communication among oral bacteria. Microbiol Mol Biol Rev (2002) 4.67
Genome analysis reveals pili in Group B Streptococcus. Science (2005) 3.85
Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science (2005) 3.83
An M protein with a single C repeat prevents phagocytosis of Streptococcus pyogenes: use of a temperature-sensitive shuttle vector to deliver homologous sequences to the chromosome of S. pyogenes. Mol Microbiol (1993) 3.76
Endocarditis and biofilm-associated pili of Enterococcus faecalis. J Clin Invest (2006) 3.33
Reducing implant-related infections: active release strategies. Chem Soc Rev (2006) 3.09
Assembly and role of pili in group B streptococci. Mol Microbiol (2006) 2.92
Biofilm formation by Streptococcus pneumoniae: role of choline, extracellular DNA, and capsular polysaccharide in microbial accretion. J Bacteriol (2006) 2.42
Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. Mol Microbiol (2006) 2.31
Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun (1993) 2.26
Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res (2002) 2.20
Dual role for pilus in adherence to epithelial cells and biofilm formation in Streptococcus agalactiae. PLoS Pathog (2009) 2.15
New genetic techniques for group B streptococci: high-efficiency transformation, maintenance of temperature-sensitive pWV01 plasmids, and mutagenesis with Tn917. Appl Environ Microbiol (1997) 2.04
Streptococcus pyogenes pili promote pharyngeal cell adhesion and biofilm formation. Mol Microbiol (2007) 2.01
Streptococcus agalactiae mastitis: a review. Can Vet J (1997) 1.96
Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun (2002) 1.94
Patterns of virulence gene expression differ between biofilm and tissue communities of Streptococcus pyogenes. Mol Microbiol (2005) 1.86
Dynamics of Streptococcus agalactiae colonization in women during and after pregnancy and in their infants. J Clin Microbiol (2004) 1.84
Group B streptococcal pilus proteins contribute to adherence to and invasion of brain microvascular endothelial cells. J Bacteriol (2006) 1.78
Biofilms: a role in recurrent mastitis infections? Vet J (2006) 1.77
Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infect Immun (2000) 1.73
Streptococcus parasanguis fimbria-associated adhesin fap1 is required for biofilm formation. Infect Immun (2001) 1.71
Perinatal infections due to group B streptococci. Obstet Gynecol (2004) 1.69
Isolation of Streptococcus pneumoniae biofilm mutants and their characterization during nasopharyngeal colonization. Infect Immun (2008) 1.66
An IgG-like domain in the minor pilin GBS52 of Streptococcus agalactiae mediates lung epithelial cell adhesion. Structure (2007) 1.64
Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis (2009) 1.64
Sortase A utilizes an ancillary protein anchor for efficient cell wall anchoring of pili in Streptococcus agalactiae. Infect Immun (2008) 1.51
A scanning electron microscopic study of urine droppers and urine collecting systems. Arch Intern Med (1983) 1.29
Group B streptococcal colonization and serotype-specific immunity in healthy elderly persons. Clin Infect Dis (2005) 1.24
Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. J Infect Dis (2006) 1.19
Relationship between expression of the family of M proteins and lipoteichoic acid to hydrophobicity and biofilm formation in Streptococcus pyogenes. PLoS One (2009) 1.18
Biofilm formation by group A Streptococcus: a role for the streptococcal regulator of virulence (Srv) and streptococcal cysteine protease (SpeB). Microbiology (2009) 1.10
Pilus backbone contributes to group B Streptococcus paracellular translocation through epithelial cells. J Infect Dis (2008) 1.06
Biofilm formation in clinical isolates of group B streptococci from north India. Microb Pathog (2009) 0.86
Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci U S A (2005) 14.59
Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A (2002) 5.28
Pili in gram-positive pathogens. Nat Rev Microbiol (2006) 4.21
Genome analysis reveals pili in Group B Streptococcus. Science (2005) 3.85
Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science (2005) 3.83
Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci U S A (2005) 3.59
Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol (2006) 3.03
A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med (2005) 2.35
Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. Mol Microbiol (2006) 2.31
Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 2.20
Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc Natl Acad Sci U S A (2003) 2.17
Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol (2006) 2.16
Streptococcus pyogenes pili promote pharyngeal cell adhesion and biofilm formation. Mol Microbiol (2007) 2.01
Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun (2002) 1.94
Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol (2002) 1.83
Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A (2010) 1.75
Comparative genomics of Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes. Microbiology (2006) 1.75
Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A (2010) 1.66
Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis (2009) 1.64
A chemokine-degrading extracellular protease made by group A Streptococcus alters pathogenesis by enhancing evasion of the innate immune response. Infect Immun (2008) 1.54
Sortase A utilizes an ancillary protein anchor for efficient cell wall anchoring of pili in Streptococcus agalactiae. Infect Immun (2008) 1.51
Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics (2006) 1.39
Emergence and global dissemination of host-specific Streptococcus agalactiae clones. MBio (2010) 1.35
Mg(2+) signalling defines the group A streptococcal CsrRS (CovRS) regulon. Mol Microbiol (2007) 1.31
Proteomics characterization of outer membrane vesicles from the extraintestinal pathogenic Escherichia coli DeltatolR IHE3034 mutant. Mol Cell Proteomics (2007) 1.30
Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol (2012) 1.29
Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc Natl Acad Sci U S A (2011) 1.27
Identification of a common immune signature in murine and human systemic Salmonellosis. Proc Natl Acad Sci U S A (2012) 1.25
Characterization of a novel Neisseria meningitidis Fur and iron-regulated operon required for protection from oxidative stress: utility of DNA microarray in the assignment of the biological role of hypothetical genes. Mol Microbiol (2004) 1.24
Structural vaccinology starts to deliver. Nat Rev Microbiol (2012) 1.22
Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. J Infect Dis (2006) 1.19
Sequence variation in group A Streptococcus pili and association of pilus backbone types with lancefield T serotypes. J Infect Dis (2008) 1.18
BibA: a novel immunogenic bacterial adhesin contributing to group B Streptococcus survival in human blood. Mol Microbiol (2007) 1.18
Role of FNR and FNR-regulated, sugar fermentation genes in Neisseria meningitidis infection. Mol Microbiol (2006) 1.17
Subunit association and conformational flexibility in the head subdomain of human CD81 large extracellular loop. Biol Chem (2002) 1.17
Protein array profiling of tic patient sera reveals a broad range and enhanced immune response against Group A Streptococcus antigens. PLoS One (2009) 1.17
Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1. Mol Cell Proteomics (2009) 1.13
Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case. Mol Cell Proteomics (2012) 1.13
Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci U S A (2011) 1.09
Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine (2010) 1.09
Pilus backbone contributes to group B Streptococcus paracellular translocation through epithelial cells. J Infect Dis (2008) 1.06
GNA33 from Neisseria meningitidis serogroup B encodes a membrane-bound lytic transglycosylase (MltA). Eur J Biochem (2002) 1.05
Capsular gene typing of Streptococcus agalactiae compared to serotyping by latex agglutination. J Clin Microbiol (2012) 1.04
Capturing host-pathogen interactions by protein microarrays: identification of novel streptococcal proteins binding to human fibronectin, fibrinogen, and C4BP. FASEB J (2009) 1.04
Scavenger receptor gp340 aggregates group A streptococci by binding pili. Mol Microbiol (2008) 1.03
Identification of new potential vaccine candidates against Chlamydia pneumoniae by multiple screenings. Vaccine (2005) 1.02
The design of semi-synthetic and synthetic glycoconjugate vaccines. Expert Opin Drug Discov (2011) 1.02
CsrRS regulates group B Streptococcus virulence gene expression in response to environmental pH: a new perspective on vaccine development. J Bacteriol (2009) 1.01
Invasive African Salmonella Typhimurium induces bactericidal antibodies against O-antigens. Microb Pathog (2013) 0.98
Staphylococcus aureus FhuD2 is involved in the early phase of staphylococcal dissemination and generates protective immunity in mice. J Infect Dis (2012) 0.98
GNA33 of Neisseria meningitidis is a lipoprotein required for cell separation, membrane architecture, and virulence. Infect Immun (2004) 0.96
Point mutations in wchA are responsible for the non-typability of two invasive Streptococcus pneumoniae isolates. Microbiology (2011) 0.96
FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio (2012) 0.95
Targeted amino acid substitutions impair streptolysin O toxicity and group A Streptococcus virulence. MBio (2013) 0.95
CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans. Infect Immun (2009) 0.95
Environmental acidification drives S. pyogenes pilus expression and microcolony formation on epithelial cells in a FCT-dependent manner. PLoS One (2010) 0.95
Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases. Vaccine (2008) 0.94
Exploiting antigenic diversity for vaccine design: the chlamydia ArtJ paradigm. J Biol Chem (2010) 0.94
Protective efficacy induced by recombinant Clostridium difficile toxin fragments. Infect Immun (2013) 0.94
Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proc Natl Acad Sci U S A (2012) 0.93
Sex chromosome alterations associate with tumor progression in sporadic colorectal carcinomas. Clin Cancer Res (2007) 0.93
Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro. J Extracell Vesicles (2013) 0.93
Streptococcus pyogenes SpyCEP influences host-pathogen interactions during infection in a murine air pouch model. PLoS One (2012) 0.92
Proteome analysis of Neisseria meningitidis serogroup A. Proteomics (2004) 0.92
Streptococcus pyogenes SpyCEP: a chemokine-inactivating protease with unique structural and biochemical features. FASEB J (2010) 0.92
Escherichia coli: great diversity around a common core. MBio (2012) 0.92
Introduction of zwitterionic motifs into bacterial polysaccharides generates TLR2 agonists able to activate APCs. J Immunol (2007) 0.91
Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc Natl Acad Sci U S A (2013) 0.91
Typing of the pilus-protein-encoding FCT region and biofilm formation as novel parameters in epidemiological investigations of Streptococcus pyogenes isolates from various infection sites. J Med Microbiol (2009) 0.90
Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides. Proc Natl Acad Sci U S A (2009) 0.89
Structure analysis and site-directed mutagenesis of defined key residues and motives for pilus-related sortase C1 in group B Streptococcus. FASEB J (2011) 0.89
A novel polyclonal antibody library for expression profiling of poorly characterized, membrane and secreted human proteins. J Proteomics (2011) 0.89
Structural and functional characterization of the Staphylococcus aureus virulence factor and vaccine candidate FhuD2. Biochem J (2013) 0.88
Group B Streptococcus crosses human epithelial cells by a paracellular route. J Infect Dis (2005) 0.88
Mining the bacterial unknown proteome: identification and characterization of a novel family of highly conserved protective antigens in Staphylococcus aureus. Biochem J (2013) 0.88
BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus. J Infect Dis (2009) 0.87
Transcriptional and proteomic profiles of group B Streptococcus type V reveal potential adherence proteins associated with high-level invasion. Infect Immun (2007) 0.87